Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic Hires New CEO as Strategy Shift Continues

NEW YORK (GenomeWeb News) – Gene Logic today said it has hired Charles Dimmler as president CEO, replacing Mark Gessler, who will remain chairman of the board.
Gene Logic took the step to help it transition into a purely drug-repositioning business. A milestone in that strategy took place last December when the company sold its preclinical division to San-Francisco-based contract research organization Bridge Pharmaceuticals for $15 million.
Dimmler, 65, has been on the financial and management ends of the biotechnology industry for two decades, and has been a director at Gene Logic for 10 years, according to Gene Logic.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.